These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30781409)

  • 21. Intratumoral spatial distribution of hypoxia and angiogenesis assessed by 18F-FAZA and 125I-Gluco-RGD autoradiography.
    Picchio M; Beck R; Haubner R; Seidl S; Machulla HJ; Johnson TD; Wester HJ; Reischl G; Schwaiger M; Piert M
    J Nucl Med; 2008 Apr; 49(4):597-605. PubMed ID: 18344437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis of a 2-nitroimidazole derivative N-(4-[
    Nario AP; Woodfield J; Dos Santos SN; Bergman C; Wuest M; Araújo YB; Lapolli AL; West FG; Wuest F; Bernardes ES
    EJNMMI Radiopharm Chem; 2022 Jun; 7(1):13. PubMed ID: 35697954
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The synthesis and radiolabeling of 2-nitroimidazole derivatives of cyclam and their preclinical evaluation as positive markers of tumor hypoxia.
    Engelhardt EL; Schneider RF; Seeholzer SH; Stobbe CC; Chapman JD
    J Nucl Med; 2002 Jun; 43(6):837-50. PubMed ID: 12050331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PET imaging of tumor hypoxia using 18F-labeled pimonidazole.
    Busk M; Jakobsen S; Horsman MR; Mortensen LS; Iversen AB; Overgaard J; Nordsmark M; Ji X; Lee DY; Raleigh JR
    Acta Oncol; 2013 Oct; 52(7):1300-7. PubMed ID: 23962243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [
    Gammon ST; Pisaneschi F; Bandi ML; Smith MG; Sun Y; Rao Y; Muller F; Wong F; De Groot J; Ackroyd J; Mawlawi O; Davies MA; Gopal YNV; Di Francesco ME; Marszalek JR; Dewhirst M; Piwnica-Worms D
    Cells; 2019 Nov; 8(12):. PubMed ID: 31766580
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative evaluation of [
    Nakata N; Kiriu M; Okumura Y; Zhao S; Nishijima KI; Shiga T; Tamaki N; Kuge Y; Matsumoto H
    Nucl Med Biol; 2019 Mar; 70():39-45. PubMed ID: 30836255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients.
    Bollineni VR; Kerner GS; Pruim J; Steenbakkers RJ; Wiegman EM; Koole MJ; de Groot EH; Willemsen AT; Luurtsema G; Widder J; Groen HJ; Langendijk JA
    J Nucl Med; 2013 Aug; 54(8):1175-80. PubMed ID: 23753185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and Bioevaluation of Novel [
    Yang X; Wang F; Zhu H; Yang Z; Chu T
    Mol Pharm; 2019 May; 16(5):2118-2128. PubMed ID: 30964298
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A limited overlap between intratumoral distribution of 1-(5-fluoro-5-deoxy-α-D-arabinofuranosyl)-2-nitroimidazole and copper-diacetyl-bis[N(4)-methylthiosemicarbazone].
    Furukawa T; Yuan Q; Jin ZH; Aung W; Yoshii Y; Hasegawa S; Endo H; Inoue M; Zhang MR; Fujibayashi Y; Saga T
    Oncol Rep; 2015 Sep; 34(3):1379-87. PubMed ID: 26134305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and evaluation of an
    Nunes PSG; Zhang Z; Kuo HT; Zhang C; Rousseau J; Rousseau E; Lau J; Kwon D; Carvalho I; Bénard F; Lin KS
    J Labelled Comp Radiopharm; 2018 Apr; 61(4):370-379. PubMed ID: 29247455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis of [
    Kniess T; Zessin J; Mäding P; Kuchar M; Kiss O; Kopka K
    EJNMMI Radiopharm Chem; 2023 Mar; 8(1):5. PubMed ID: 36897480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of [18F]-FMISO, [18F]-FAZA and [18F]-HX4 for PET imaging of hypoxia--a simulation study.
    Wack LJ; Mönnich D; van Elmpt W; Zegers CM; Troost EG; Zips D; Thorwarth D
    Acta Oncol; 2015; 54(9):1370-7. PubMed ID: 26203928
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In Vivo Ester Hydrolysis as a New Approach in Development of Positron Emission Tomography Tracers for Imaging Hypoxia.
    Zhang L; Yao X; Cao J; Hong H; Zhang A; Zhao R; Zhang Y; Zha Z; Liu Y; Qiao J; Zhu L; Kung HF
    Mol Pharm; 2019 Mar; 16(3):1156-1166. PubMed ID: 30676751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preparation of the hypoxia imaging PET tracer [18F]FAZA: reaction parameters and automation.
    Reischl G; Ehrlichmann W; Bieg C; Solbach C; Kumar P; Wiebe LI; Machulla HJ
    Appl Radiat Isot; 2005 Jun; 62(6):897-901. PubMed ID: 15799867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro and in vivo evaluation of [(18)F]F-GAZ, a novel oxygen-mimetic azomycin-glucose conjugate, for imaging hypoxic tumor.
    Wuest M; Kumar P; Wang M; Yang J; Jans HS; Wiebe LI
    Cancer Biother Radiopharm; 2012 Oct; 27(8):473-80. PubMed ID: 22746267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An exploratory study of volumetric analysis for assessing tumor response with (18)F-FAZA PET/CT in patients with advanced non-small-cell lung cancer (NSCLC).
    Kerner GS; Bollineni VR; Hiltermann TJ; Sijtsema NM; Fischer A; Bongaerts AH; Pruim J; Groen HJ
    EJNMMI Res; 2016 Dec; 6(1):33. PubMed ID: 27090118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of 18F-fluoroazomycin-arabinofuranoside and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) in preclinical models of cancer.
    Valtorta S; Belloli S; Sanvito F; Masiello V; Di Grigoli G; Monterisi C; Fazio F; Picchio M; Moresco RM
    J Nucl Med; 2013 Jul; 54(7):1106-12. PubMed ID: 23699667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ¹⁸F-HX4 hypoxia imaging with PET/CT in head and neck cancer: a comparison with ¹⁸F-FMISO.
    Chen L; Zhang Z; Kolb HC; Walsh JC; Zhang J; Guan Y
    Nucl Med Commun; 2012 Oct; 33(10):1096-102. PubMed ID: 22836736
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.